ER、PR、HER-2表达与乳腺癌骨转移的相关性研究

摘要

Objective:To observe the expression of estrogen receptor (ER),progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) on breast cancer patients with bone metastasis,and try to find the correlation between them and to evaluate it for the prediction of breast cancer bone metastasis.Methods:The 184 breast cancer bone metastasis patients were divided into three groups:Bone-only metastases group (44 cases),bone + lymph node metastasis group (36 cases) bone + visceral metastasis group (104 cases),the above-mentioned immunohistochemical markers of these three groups were analyzed,and then to evaluate the predictive value of ER,PR and HER-2 with the breast cancer bone metastasis.Results:The incidence of breast cancer bone metastasis was 8.4％.And among all the ER positive-only individuals,the bone metastasis-only group vs bone + lymph nodes metastasis group,P =0.258,P ＞ 0.05.The bone metastasis-only group vs the bone + visceral metastasis group,P =0.000,P ＜ 0.05.Bone + lymph nodes metastasis group vs bone + visceral metastasis group,P =0.004,P ＜ 0.05.As for other molecular phenotype breast cancer patients,no significant difference was found (P ＞ 0.05).Conclusion:ER positive-only breast cancer are prone to migrate to the bone.It is recommended to strengthen the examinations about the bone metastasis and ought to provide preventive treatment for these patients.%目的:观察乳腺癌骨转移患者雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER-2)表达情况,为ER、PR、HER-2应用于预测乳腺癌骨转移提供依据.方法:收集确诊的乳腺癌骨转移患者184例,根据有无淋巴结、内脏转移分为3组:单纯骨转移组(44例),骨+淋巴结转移组(36例),骨+内脏转移组(104例),对3组患者的上述免疫组化指标进行统计分析,评估这些指标在乳腺癌骨转移中的预测价值.结果:乳腺癌骨转移发生率为8.4％;ER单独阳性患者中,单纯骨转移组vs骨+淋巴结转移组,P=0.258,P＞0.05;单纯骨转移组vs骨+内脏转移组,P =0.000,P＜0.05;骨+淋巴结转移组vs骨+内脏转移组,P=0.004,P＜0.05;其它分子表型组间比较,差异无统计学意义(P＞0.05).结论:ER单独阳性乳腺癌患者最易发生单纯骨转移,对这部分患者,建议加强骨转移相关检查,给予预防性双膦酸盐治疗.